STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.
Also called NCT01927068
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 499 participants
- Sponsor
- Registry
-
NCT01927068
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Austria, Belgium, France, Germany, Italy, New Zealand, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01927068. Non-randomized; no masking; primary purpose treatment. Start 2013-07 (actual); primary completion 2020-08 (actual). Results posted on 2022-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
- Acronym
- ILLUMENATE
- Condition
- Peripheral Arterial Disease
- Intervention (Device)
- Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
- Lead sponsor
- Spectranetics Corporation
Record details
- Record id
cardio:ct-nct01927068- Content hash
faf8d13941f83e2b09b945b893bdb38e41098bf5c2474960e2a477f08a9c8a0a